Skip to Main Content

Paper Details

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.
Leukemia
81
2012
Author NameAffiliation
Anagha DeshpandeBrigham and Women's Hospital and Harvard Medical School
  • 1 - 1

Datasets

Release 1.2